Research programme: anti-CMV monoclonal antibodies - AVANIRAlternative Names: Anti-CMV monoclonal antibodies research programme - AVANIR
Latest Information Update: 17 Mar 2017
At a glance
- Originator Avanir Pharmaceuticals
- Class Monoclonal antibodies
- Mechanism of Action Immunomodulators
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cytomegalovirus infections
Most Recent Events
- 14 Mar 2006 No development reported - Preclinical for Cytomegalovirus infections treatment in USA (unspecified route)
- 08 May 2003 Preclinical trials in Cytomegalovirus infections in USA (unspecified route)